EGFR Non-Small Cell Lung Cancer Global Market Report 2026

Epidermal growth factor receptor (EGFR) non-small cell lung cancer is a subtype of non-small cell lung cancer marked by mutations or changes in the epidermal growth factor receptor gene, which is essential for cell growth and division. These genetic alterations cause uncontrolled tumor proliferation and progression in lung tissue. EGFR non-small cell lung cancer is typically managed using targeted therapies aimed at blocking abnormal receptor signaling to slow disease progression.

The primary drug types of epidermal growth factor receptor (EGFR) non-small cell lung cancer include tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and late phase drugs. Tyrosine kinase inhibitors (TKIs) refer to targeted therapies that inhibit the enzymatic activity of the EGFR protein, preventing cancer cell proliferation and tumor growth. These drugs are used for mutation types including exon 19 deletions, exon 21 L858R substitution mutations, exon 20 insertion mutations, and other mutation types. They are available in treatment types such as monotherapy and combination therapy, and administered via oral or intravenous routes. They are used by end users including hospitals, specialty oncology centers, cancer research institutes, academic institutes, and other end users.

Tariffs are impacting the EGFR non-small cell lung cancer market by increasing costs of imported active pharmaceutical ingredients, companion diagnostic kits, biomarker testing reagents, and specialized oncology equipment. Oncology treatment providers in North America and Europe are most affected due to reliance on imported targeted therapies and diagnostics, while Asia-Pacific faces cost pressures on drug manufacturing and export activities. These tariffs are influencing treatment affordability and supply chain planning. However, they are also supporting regional drug manufacturing, localized diagnostic kit production, and expanded investment in domestic oncology research and development.

The egfr non-small cell lung cancer market research report is one of a series of new reports from The Business Research Company that provides egfr non-small cell lung cancer market statistics, including egfr non-small cell lung cancer industry global market size, regional shares, competitors with a egfr non-small cell lung cancer market share, detailed egfr non-small cell lung cancer market segments, market trends and opportunities, and any further data you may need to thrive in the egfr non-small cell lung cancer industry. This egfr non-small cell lung cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The egfr non-small cell lung cancer market size has grown strongly in recent years. It will grow from $9.34 billion in 2025 to $10.07 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of non-small cell lung cancer, advancements in molecular diagnostics, rising awareness of egfr mutation testing, expansion of oncology specialty centers, increased availability of targeted therapies.

The egfr non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $13.74 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing pipeline of next-generation egfr inhibitors, rising adoption of precision oncology approaches, expansion of biomarker-driven treatment models, growing integration of real-world evidence in oncology care, increasing focus on patient-centric cancer management. Major trends in the forecast period include increasing adoption of targeted egfr therapies, rising use of companion diagnostic testing, growing focus on personalized treatment pathways, expansion of combination therapy approaches, enhanced integration of multidisciplinary cancer care.

The increasing emphasis on personalized medicine approaches is anticipated to accelerate the growth of the epidermal growth factor receptor (EGFR) non-small cell lung cancer market in the future. Personalized medicine is a healthcare approach that customizes prevention, diagnosis, and treatment strategies based on individual genetic, environmental, and lifestyle characteristics. The adoption of personalized medicine approaches is rising due to greater access to genetic and molecular profiling, which enables accurate identification of disease-specific targets and allows treatments to be tailored for improved patient outcomes. Personalized medicine approaches support EGFR non-small cell lung cancer treatment by identifying specific EGFR mutations in patients, enabling physicians to prescribe targeted therapies that improve effectiveness while reducing side effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized therapies for rare disease patients in 2023, compared with six approvals in 2022. Therefore, the increasing emphasis on personalized medicine approaches is boosting the growth of the EGFR non-small cell lung cancer market.

Leading companies operating in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market are focusing on developing innovative products, such as antibody-drug conjugates, to enhance treatment effectiveness while minimizing systemic side effects compared to traditional chemotherapy. An antibody-drug conjugate is a targeted therapy that connects a cancer-specific antibody to a potent drug, delivering treatment directly to tumor cells while sparing healthy tissue. For instance, in June 2025, AstraZeneca Plc, a UK-based biopharmaceutical company, announced that Datroway (datopotamab deruxtecan or Dato-DXd) received approval in the US for treating adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who had previously undergone EGFR-targeted therapy and platinum-based chemotherapy. This indication received accelerated approval based on observed objective response rate and duration of response, with continued approval dependent on confirmatory trials. The US FDA granted approval following Priority Review and Breakthrough Therapy Designation, supported by subgroup analysis from the TROPION-Lung05 Phase II trial and evidence from the TROPION-Lung01 Phase III trial.

In October 2023, Daiichi Sankyo, a Japan-based pharmaceutical company specializing in treatments for EGFR non-small cell lung cancer, partnered with Merck Co. Inc. to jointly develop and commercialize three DXd antibody-drug conjugate candidates. Under this collaboration, both companies will co-develop atritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan globally, while Daiichi Sankyo retains exclusive rights in Japan and responsibility for manufacturing and supply. Notably, patritumab deruxtecan received breakthrough therapy designation from the US Food and Drug Administration for patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who progressed after specific therapies. Merck Co. Inc. is a US-based pharmaceutical company.

Major companies operating in the egfr non-small cell lung cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca Plc, Bayer AG, Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., ShanghAI Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., and Cullinan Therapeutics Inc.

North America was the largest region in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egfr non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the egfr non-small cell lung cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epidermal growth factor receptor (EGFR) non-small cell lung cancer market consists of revenues earned by entities by providing services such as pathological and diagnostic evaluation, personalized treatment planning, immunotherapy support services, radiation oncology services, patient consultation and clinical management, adverse event management, and supportive and palliative care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The epidermal growth factor receptor (EGFR) non-small cell lung cancer market also includes sales of companion diagnostic kits, biomarker testing assays, supportive care drugs, and combination chemotherapy regimens. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

EGFR Non-Small Cell Lung Cancer Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses egfr non-small cell lung cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for egfr non-small cell lung cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The egfr non-small cell lung cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Late Phase
• 2) By Mutation Type: Exon 19 Deletions; Exon 21 L858R Substitution Mutations; Exon 20 Insertion Mutations; Other Mutation Types
• 3) By Treatment Type: Monotherapy; Combination Therapy
• 4) By Route of Administration: Oral; Intravenous
• 5) By End User: Hospitals; Specialty Oncology Centers; Cancer Research Institutes; Academic Institutes; Other End Users
• Subsegments:
• 1) By Tyrosine Kinase Inhibitors: First Generation Tyrosine Kinase Inhibitors; Second Generation Tyrosine Kinase Inhibitors; Third Generation Tyrosine Kinase Inhibitors
• 2) By Monoclonal Antibodies: Anti Epidermal Growth Factor Receptor Monoclonal Antibodies; Dual Target Monoclonal Antibodies; Antibody Drug Conjugates
• 3) By Late Phase: Patritumab Deruxtecan; Other Late Phase Pipeline Therapies
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca Plc; Bayer AG; Eli Lilly and Company; Takeda Pharmaceuticals Company Ltd.; Boehringer Ingelheim Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.; Daiichi Sankyo Co. Ltd.; Taiho Pharmaceutical Co. Ltd.; Jiangsu Hansoh Pharmaceutical Co. Ltd.; Betta Pharmaceuticals Co. Ltd.; ShanghAI Allist Pharmaceuticals Co. Ltd.; Oric Pharmaceuticals Inc.; Black Diamond Therapeutics Inc.; G1 Therapeutics Inc.; Dizal Pharmaceutical; ArriVent BioPharma Inc.; and Cullinan Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.